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Abstract: Rheumatoid arthritis is a chronic, progressive autoimmune disease associated with 
inflammation and destruction of joints and systemic effects, which result in significant impact 
on patient’s quality of life and function. Tofacitinib was approved for the treatment of rheuma-
toid arthritis in the USA in 2012 and subsequently in other countries, but not by the European 
Medicines Agency. The goal of this review was to evaluate the impact of tofacitinib on patient-
reported and patient-specific outcomes from prior clinical studies, focusing on quality of life, 
functionality, pain, global disease assessment, major adverse consequences, and withdrawals. 
A total of 13 reports representing 11 clinical studies on tofacitinib in rheumatoid arthritis 
were identified through PubMed and reference lists in meta-analyses and other reviews. Data 
on improvements in patient-driven composite tools to measure disease activity in rheumatoid 
arthritis, such as the Health Assessment Questionnaire, served as a major outcome evaluated in 
this review and were extracted from each study. Additional data extracted from those clinical 
studies included patient assessment of pain (using a 0–100 mm visual analog scale), patient 
global assessment of disease (using a 0–100 mm visual analog scale), patient withdrawals, 
withdrawals due to adverse effects or lack of effect, and risk of serious adverse effects, serious 
infections, and deaths. Tofacitinib 5 mg bid appears to have a favorable impact on patient out-
comes related to efficacy and safety when compared with baseline values and with comparator 
disease-modifying antirheumatic drugs and placebo. Improvements were seen in the composite 
and individual measures of disease activity. Serious adverse effects, other adverse consequences, 
overall withdrawals, and withdrawals due to adverse effects and lack of efficacy are similar or 
more favorable for tofacitinib versus comparator disease-modifying antirheumatic drugs and 
placebo. At this point, tofacitinib appears to have an important role in the treatment of rheuma-
toid arthritis through improvement in these patient outcomes. However, it may require years of 
additional clinical studies and postmarketing surveillance to fully characterize the benefit-to-risk 
ratio of tofacitinib in a larger and diverse patient population.
Keywords: tofacitinib, rheumatoid arthritis, patient-reported outcomes, quality of life
Introduction
Rheumatoid arthritis is a chronic, progressive autoimmune disease of joints associated 
with inflammation and destruction of joints and systemic effects.1,2 The most recent 
rheumatoid arthritis treatment guidelines were developed by the American College of 
Rheumatology (ACR) in 2012, the European Union League Against Rheumatism in 2013, 
and Canada in 2012.3–5 Tofacitinib was approved as a second-line treatment for moderate-
to-severe rheumatoid arthritis in patients who have inadequate response or intolerance 
to methotrexate in the USA in 2012 at 5 mg bid. It was subsequently approved in Japan, 
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Switzerland at both 5 and 10 mg bid.6 However, in 2013, the 
European Medicines Agency (EMA) did not approve tofaci-
tinib after two reviews due to concerns related to the risks of 
serious infections and other severe adverse effects.7 Tofaci-
tinib is now approved in 40 countries and Pfizer Laboratories 
(New York, USA) plans to resubmit to the EMA for approval 
later in 2015.8 The US Food and Drug Administration (FDA) 
approved tofacitinib with labeling that includes warnings on 
serious infections and malignancies.9 The warnings are similar 
to those seen in the labeling for biologic disease-modifying 
antirheumatic drugs (DMARDs) used in the treatment of 
rheumatoid arthritis. Tofacitinib does not appear in the ACR 
or Canadian guidelines but is mentioned in the European 
Union League Against Rheumatism guidelines. The clinical 
use and sale of tofacitinib continues to expand, particularly 
in the USA.10,11 The impact of tofacitinib on the clinical and 
laboratory measures of rheumatoid arthritis (ACR20, ACR50, 
ACR70, DAS28, etc) is well documented in reviews and meta-
analyses,12–20 but these do not focus on the impact on outcomes 
from the patient’s perspective and do not include the latest 
studies. Patient-reported outcomes data are provided in almost 
all published studies and may also be provided as additional 
details in subanalyses of original studies or supplementary 
data. Pharmacoeconomic analyses were not included in this 
review in order to focus specifically on patient-reported and 
patient-related outcomes documented in clinical studies. The 
objectives of this review are to collect and evaluate data related 
to the impact of tofacitinib on patient-reported outcomes (qual-
ity of life, functionality, pain, and global disease assessment), 
major adverse consequences, and withdrawals.
Methods
Clinical studies on tofacitinib in rheumatoid arthritis served 
as the primary source for the data collected in this review. 
The selection criteria also included studies or reports writ-
ten in English, blinded and open-label studies, prospective 
and retrospective, containing the original publication of the 
data, and data provided on at least one of the patient-specific 
outcome measures noted as follows. The studies were identi-
fied through a number of methods, initially through PubMed 
searches using the following search terms: tofacitinib, 
CP-690550, and rheumatoid arthritis and limiting the search 
to clinical studies. The same terms were used in searching 
for articles in the following databases: Cochrane Library, 
EBSCO Medline Complete, International Pharmaceutical 
Abstracts, ScienceDirect, and Scopus. The reference lists in 
meta-analyses and review articles on tofacitinib were also 
searched for clinical studies.
Selection criteria for the studies included any studies that 
were prospective Phase II, Phase III, or other original studies 
evaluating efficacy and/or safety of tofacitinib in rheuma-
toid arthritis. The authors extracted specific data from each 
study and any supplementary documents provided and then 
tabulated data on one or more specific outcomes. Data were 
verified through review by at least one other author.
Each of the studies selected was searched for data within 
each of the following general categories measures: patient-
 reported composite measures and specific measures of dis-
ease outcomes, withdrawals, and serious adverse effects or 
consequences. The patient-reported composite measures of 
disease outcomes evaluated in each study, based on recom-
mendations from the ACR and other rheumatology societies 
and experts, included: Health Assessment Questionnaire 
(HAQ, HAQ-II, and HAQ-Disability Index [HAQ-DI]), 
Functional Assessment of Chronic Illness Therapy Fatigue 
Scale, Short Form 36-Item Health Survey, Short Form 36-Item 
Arthritis Specific Health Index, Patient Activity Scale, Patient 
Activity Scale II, Routine Assessment of Patient Index Data 
with 3 measures, Arthritis Impact Measurement Scale (AIMS, 
AIMS2), European Quality of Life Measure, Multidimen-
sional Health Assessment Questionnaire, Modified Health 
Questionnaire, and Rheumatoid Arthritis Quality of Life.21–24 
The patient-reported specific measures of disease activity 
included patient assessment of pain (using a 0–100 mm visual 
analog scale) and the patient global assessment of disease 
(using a 0–100 mm visual analog scale). Withdrawal data 
used in this review included total withdrawals, withdrawals 
due to lack of efficacy, and withdrawals due to adverse effects. 
The data on serious adverse effects or consequences included 
serious adverse effects, serious infections, cancers, and deaths 
that occurred during the studies.21–24
The data extracted included improvement from baseline 
in units measured and percent improvement from baseline 
for HAQ-DI, patient assessment of pain, patient global 
assessment of disease, and other measures. Therefore, these 
numbers are positive in value to demonstrate improvement 
rather than the negative values reported in the studies that 
reflect improvement in those measures. Frequency counts and 
the percent of those counts based on the size of the entering 
groups were provided for the other measures. Percentages 
and visual analog scale results were rounded off to whole 
numbers.
The recommended dose for tofacitinib in the USA is 5 mg 
bid,9 but lower and higher dosages have been used in clinical 
studies, and approval in Russia and Switzerland includes both 
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Tofacitinib and patient outcomes in rheumatoid arthritis
1 and 3 mg bid dosage groups were combined, data from 10 bid 
and 20 mg once-daily dosage groups were combined, and data 
from 15 and 30 mg bid dosage groups were combined. Data 
from the 5 mg bid groups were listed separately.
Results
A total of 12 clinical studies reported in 14 articles were 
identified, met the selection criteria, and were used in this 
review (Table 1).25–44 Two reports, which included subanaly-
ses of data from studies, were also included.25,26,33,37 Recent 
reports that did not meet the selection criteria included a 
Phase I study, which was short in duration and lacked effi-
cacy measures.39 A report of pooled adverse effect data from 
13 studies was not the original study reporting those data, 
but select data from that report was used in describing the 
risk factors for serious infections.40
Another report of pooled data from studies was used to 
provide data on the development of cancers in patients on 
tofacitinib.41 A total of eleven studies were double-blind 
and randomized and one study was an open-label long-term 
extension study.25,27–36,38 All studies were parallel in design 
and a few studies also included a sequential design for 
patients who started on placebo and were placed on tofaci-
tinib after 3–6 months (Table 1). Tofacitinib was compared 
with placebo, methotrexate, and/or adalimumab as mono-
therapy in five double-blind studies.25,28,30,35,38 Tofacitinib was 
combined with methotrexate or other nonbiologic DMARDs 
in the other six double-blind studies,27,29,31–34 including one 
study that compared tofacitinib, adalimumab, and placebo 
in patients also receiving methotrexate.31
Patient-reported composite health 
assessment measures
All 12 studies used the HAQ-DI as the primary patient-
reported composite health assessment measure and 3 stud-
ies used additional patient-reported composite measures 
(Table 2). A change from baseline of greater than 0.22 is 
widely considered to be the minimum clinically important 
difference.22,27,30 However, one study used the threshold of 
a change of greater than 0.3 in classifying those as being 
HAQ-DI responders.26 Across most dosage ranges studied, 
tofacitinib showed clinically or statistically significant 
changes in baseline HAQ-DI scores when compared with pla-
cebo or comparator drug (Table 2). Changes in the HAQ-DI 
score were dose dependent in the vast majority of the studies 
using multiple dosages showing a greater improvement in 
the higher dosages, with one exception.29 Tofacitinib 5 mg 
bid, the currently approved and most commonly studied 
dosage, was associated with average changes in HAQ-DI 
ranging from 0.4 to 0.9, all above the threshold of 0.22 for a 
clinical important improvement. Of the 12 studies reporting 
HAQ-DI findings, 9 showed a statistically significant change 
in HAQ-DI for tofacitinib 5 mg bid compared with placebo 
or comparator drug.
Additional patient-reported composite health assessment 
measurement tools were used in four reports. The Functional 
Assessment of Chronic Illness Therapy-fatigue instrument 
demonstrated that tofacitinib 5 and 10 mg bid were statisti-
cally superior to placebo.30,34 The Short Form 36-item survey 
instrument demonstrated statistically significant improvement 
in the physical component scale in all studies reporting this 
outcome, but only in two studies for the mental component 
scale when comparing tofacitinib 5 mg bid monotherapy and 
combination therapy with placebo (Table 2).26,27,37,38 Some 
improvement was seen in the Medical Outcomes Study Sleep 
Scale, but it was not statistically significant.37
Measures of health status improved either clinically, 
statistically, or both, in all studies investigating tofacitinib 
5 mg bid against baseline, placebo, or comparator drug 
when studied as monotherapy or in combination with other 
agents. Studies, which ranged in length from 6 weeks to 
60 months, showed benefits in health status early in treat-
ment and continued through longer periods of time. Given 
the studies that have been conducted so far, tofacitinib 
shows definite improvement in patient’s quality of life and 
functional domains.
Patient’s assessment of pain and patient’s 
global assessment of disease
Data on patient’s assessment of pain and/or patient’s global 
assessment of disease were available in seven clinical 
studies (Table 3). Improvements in pain and global assess-
ments were similar within each group when comparing 
monotherapy with combination therapy studies, except for 
the tofacitinib low-dose groups (1–3 mg bid). Tofacitinib 
5 mg bid was associated with a 45%–54% improvement in 
patient’s assessment of pain and a 44%–60% improvement 
in patient’s global assessment of disease. The tofacitinib 
1–3 mg bid dosage groups were associated with less to simi-
lar improvement (23%–56%) and the tofacitinib 10–30 mg 
bid dosage groups were associated with similar to slightly 
higher improvements (39%–62%) in pain and global assess-
ment of disease. However, placebo was associated with less 
improvement, ranging from 15% to 29% improvement in 
patient’s assessment of pain ratings and 23%–39% improve-
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Table 1 Studies included in this review of patient outcomes associated with the use of tofacitinib in rheumatoid arthritis






Tofacitinib DMARD monotherapy studies
Phase ii, double-blind 5 mg bid (61) 
15 mg bid (69) 
30 mg bid (69)
Placebo (65) 6 weeks25,26
Phase ii, double-blind 1 mg bid (54) 
3 mg bid (51) 
5 mg bid (49) 
10 mg bid (61) 




Phase iii, double-blind 5 mg bid (243) 
10 mg bid (245) 
Placebo then 5 or 10 mg bid (120)a
6 months30
Phase iii, double-blind 5 mg bid (373) 
10 mg bid (397)
Methotrexate (186) 24 months35
Phase ii, double-blind 1 mg bid (53) 
3 mg bid (53) 
5 mg bid (52) 
10 mg bid (53) 
15 mg bid (54)
Placebo (52) 12 weeks38
Tofacitinib plus methotrexate or other nonbiologic DMARD studies
Phase ii, double-blind Methotrexate plus: 
1 mg bid (28) 
3 mg bid (28) 
5 mg bid (28) 




Phase ii, double-blind Methotrexate plus: 
1 mg bid (71) 
3 mg bid (68) 
5 mg bid (71) 
10 mg bid (75) 
15 mg bid (75) 




Phase iii, double-blind Methotrexate plus: 
5 mg bid (204) 
10 mg bid (201) 
Placebo then 5 mg bid (56)a 





Phase iii, double-blind Methotrexate plus: 
5 mg bid (321) 
10 mg bid (316) 
Placebo then 5 mg bid (81)a 
Placebo then 10 mg bid (79)a
12 months32
Double-blind Nonbiologic DMARD plus: 
5 mg bid (318) 
10 mg bid (318) 
Placebo then 5 mg bid (79)a 
Placebo then 10 mg bid (80)a
1 year34
Phase iii, double-blind Methotrexate plus: 
5 mg bid (133) 
10 mg bid (134) 
Placebo then 5 mg bid (66)a 
Placebo then 10 mg bid (66)a
6 months33,37
Tofacitinib monotherapy and combination DMARD study
Open-label, long-term extension with/without nonbiologic DMARDs: 
5–10 mg bid (4,102)
48 months36
Note: aOn placebo for 3–6 months, then randomly assigned to tofacitinib at the dose indicated.
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Tofacitinib and patient outcomes in rheumatoid arthritis
In monotherapy studies, methotrexate was associated with 
47% improvements in patient’s assessment of pain and global 
assessment of disease, which was comparable to tofacitinib 
5 mg bid.35 Adalimumab was associated with 30%–32% 
improvements in patient’s assessment of pain and global 
assessment of disease, which are lower than those seen with 
tofacitinib 5 mg bid.28 In summary, tofacitinib is associated 
with improvements in patient-reported assessment of pain 
and global assessment of disease.
Total withdrawals and withdrawals  
due to lack of efficacy
Total withdrawals and withdrawals due to lack of efficacy 
for tofacitinib, comparators, and placebo demonstrate possi-
ble trends across type of study (monotherapy vs combination 
therapy), tofacitinib dose, and duration of study (Table 4). 
Tofacitinib as monotherapy is associated with fewer total 
withdrawals (range 5%–21%) compared with tofacitinib as 
combination therapy with other DMARDs (range 14%–25%) 
Table 2 HAQ-Di and other composite measures
Outcome Improvement from baseline in units (%) Duration and 
referenceTofacitinib Placebo Comparator 
DMARD1–3 mg bid 5 mg bid 10 mg bid  
or 20 mg od
15–30 mg  
bid
Tofacitinib DMARD monotherapy studies
HAQ-Di 0.6 (35%) 0.7 (44%) 0.3 (18%) 6 weeks25
HAQ-Di 0.6* 0.74* (30 mg bid) 0.2 6 weeks26
HAQ-Di 0.25–0.44 (16%–29%) 0.51 (36%) 0.66 (44%) 0.82 (51%) 0.25 (16%) Adalimumab  
0.35 (24%)
24 weeks28
HAQ-Di 0.50* 0.57* 0.19 6 months30
HAQ-Di 0.9 (60%)* 1.0 (67%)* Methotrexate  
0.7 (47%)
24 months35
HAQ-Di responders# (57%)* (76%)* (36%) 6 weeks26
HAQ-Di responders# (53%)* (56%) (32%) 6 months30
HAQ-Di responders# (55%)* (74%)* (82%)* (73%)* (21%) 12 weeks38
FACiT-Fatigue 6.7* 8.0* 2.8 6 months30
FACiT-Fatigue 2.5–5.4* 7.5* 8.5* 8.0* –1.4 12 weeks38
SF-36 PCS 8.3* 9.9* 2.7 6 weeks26
SF-36 MCS 5.3 9.81* 2.64 6 weeks26
SF-36 PCS responders$ (62%)* (82%)* (86%)* (83%)* (25%) 12 weeks38
SF-36 MCS responders$ (45%) (74%)* (66%) (56%) (27%) 12 weeks38
Tofacitinib plus methotrexate or other nonbiologic DMARD studies
HAQ-Di 0.38–0.41 (32%–35%)¶ 0.49 (41%)* 0.57 (48%)* 0.05 (4%) 12 weeks27
HAQ-Di 0.34–0.48 (22%–35%)* 0.49 (34%)* 0.39–0.53 
(29%–36%)*
0.43 (30%)* 0.16 (13%) 24 weeks29
HAQ-Di 0.55 (37%)* 0.61 (44%)* 0.24 (16%) Adalimumab  
0.49 (33%)
12 months31
HAQ-Di 0.40 (28%) 0.54 (39%)* 0.15 (11%) 12 months32
HAQ-Di 0.44 (31%)* 0.53 (37%)* 0.16 (12%) 1 year34
HAQ-Di 0.43 (27%)* 0.46 (31%)* 0.18 (11%) 6 months33
HAQ-Di responders# (54%–63%)* (79%)* (81%)* (33%) 12 weeks27
FACiT-Fatigue 5.8^,* 6.8^,* 2.0^ 1 year34
FACiT-Fatigue 6.3* 4.6^,* 1.1 6 months37
SF-36 PCS 5.7 (18%)* 6.6 (20%)* 2.0 (7%) 6 months37
SF-36 PCS responders$ (75%)¶ (79%)* (76%)* (25%) 12 weeks27
SF-36 PCS responders$ (68%)* (66%)* (49%) 6 months37
SF-36 MCS 3.5 (8%)* 4.0 (9%)* 0.4 (1%) 6 months37
SF-36 MCS responders$ (58%)¶ NR NR (29%) 12 weeks27
SF-36 MCS responders$ (54%)* (50%)* (37%) 6 months37
MOS-SS 6.8 (16%) 5.8 (14%) 3.8 (8%) 6 months37
Tofacitinib monotherapy and combination DMARD study
HAQ-Di 0.8 (57%) 60 months36
Notes: *P,0.05 for tofacitinib at this dose versus placebo or comparator; ¶P,0.05 for tofacitinib at this dose versus placebo or comparator for only one of the two groups; 
#HAQ-Di responders = improvement of $0.22 or $0.30 units on HAQ-Di; $SF-36 MCS or PCS responders = improvement of $2.5 units from baseline on SF-36 MCS or 
PCS; ^estimated from a graph presented in the published study.
Abbreviations: bid, twice daily; DMARD, disease-modifying antirheumatic drug; FACiT-Fatigue, Functional Assessment of Chronic illness Therapy-fatigue instrument; 
HAQ-Di, Health Assessment Questionnaire-Disability index; MOS-SS, Medical Outcomes Study Sleep Scale; SF-36, Short Form 36-item survey instrument; SF-36 MCS, SF-36 
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Table 4 Withdrawals in general and withdrawals due to lack of efficacy in tofacitinib studies
Event Number of events (% of group) Duration and 
referenceTofacitinib Placebo Comparator 
DMARD1–3 mg bid 5 mg bid 10 mg bid  
or 20 mg od
15–30 mg bid
Tofacitinib DMARD monotherapy studies
wd all 3 (5%) 26 (19%) 17 (26%) 6 weeks25
wd all 22 (21%) 6 (12%) 6 (10%) 5 (9%) 16 (27%) Adalimumab 
16 (30%)
24 weeks28
wd all 6 (6%) 2 (4%) 4 (8%) 2 (4%) 4 (8%) 12 weeks38
Wd inefficacy 1 (2%) 2 (1%) 8 (12%) 6 weeks25
Wd inefficacy 6 (6%) 1 (2%) 1 (2%) 0 4 (7%) Adalimumab 
5 (9%)
24 weeks28
Wd inefficacy 2 (2%) 0 0 0 2 (4%) 12 weeks38
Tofacitinib plus methotrexate or other nonbiologic DMARD studies
wd all 7 (13%) 5 (18%) 7 (25%) 5 (18%) 12 weeks27
wd all 20 (14%) 15 (21%) 22 (14%) 15 (20%) 15 (22%) 24 weeks29
wd all 38 (19%) 44 (23%) 6 (5%) 6 months33
wd all 71 (22%) 51 (16%) 12 months32
wd all 53 (17%) 64 (20%) 13 (8%) 1 year34
Wd inefficacy 1 (2%) 0 0 1 (4%) 12 weeks27
Wd inefficacy 2 (1%) 1 (1%) 1 (1%) 0 5 (7%) 24 weeks29
Wd inefficacy 5 (3%) 11 (6%) 2 (2%) 6 months33
Wd inefficacy 7 (2%) 3 (1%) 12 months32
Wd inefficacy 16 (4%) 12 (4%) 1 year34
Tofacitinib monotherapy and combination DMARD study
wd all 852 (21%) 60 months36
Abbreviations: bid, twice daily; DMARD, disease-modifying antirheumatic drug; wd, withdrawal.
Table 3 Patient-reported assessment of pain and global assessment of disease in tofacitinib studies
Outcome Improvement from baseline in units (%) Duration and 
referenceTofacitinib Placebo Comparator 
DMARD1–3 mg bid 5 mg bid 10 mg bid  
or 20 mg od
15–30 mg bid
Tofacitinib DMARD monotherapy studies
Paina 34 (50%) 40–44 (59%–66%) 10 (15%) 6 weeks25
Paina 14–18 (23%–29%) 31 (48%) 34 (54%) 36 (56%) 17 (27%) Adalimumab  
21 (32%)
24 weeks28
Paina 32 (54%) 35 (58%) Methotrexate  
28 (47%)
24 months35
Patient globala 35 (50%) 39–40 (61%–62%) 15 (23%) 6 weeks25
Patient globala 16–19 (26%–32%) 31 (46%) 33 (53%) 36 (57%) 16 (27%) Adalimumab  
19 (30%)
24 weeks28
Patient globala 32 (53%) 35 (58%) Methotrexate  
27 (47%)
24 months35
Tofacitinib plus methotrexate or other nonbiologic DMARD studies
Paina 23–33 31 38 6 12 weeks27
Paina 22–24 (37%–44%)* 27 (50%)* 22–26 (39%–43%)* 24 (43%)* 13 (25%) 24 weeks29
Paina 27* 25* 8 6 months33
Paina 26 (45%)* 30 (52%)* 16 (29%) 12 months32
Patient globala 27–38 38 38 7 12 weeks27
Patient globala 28–32 (44%–56%)* 34 (60%)* 30–34 (51%–56%)* 37 (61%)* 23 (39%) 24 weeks29
Patient globala 26 (44%)* 29 (51%)* 14 (25%) 12 months32
Notes: *P,0.05 versus placebo or comparator; apatient assessment of pain and global assessment of disease on a 0–100 mm visual analog scale.
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Tofacitinib and patient outcomes in rheumatoid arthritis
and adalimumab monotherapy (30%) or placebo monother-
apy (26%–27%). However, there is no apparent consistent 
pattern of differences in total withdrawal rates in combina-
tion therapy studies comparing tofacitinib with placebo or 
among the different doses of tofacitinib in monotherapy and 
combination therapy studies (Table 4).
The withdrawal rates due to lack of efficacy are lower for 
tofacitinib monotherapy groups (range 0%–6%) compared with 
adalimumab and placebo monotherapy groups (range 7%–12%). 
However, the withdrawal rates due to lack of efficacy were 
similar for tofacitinib monotherapy groups (range 0%–6%), 
tofacitinib–DMARD combination groups (range 0%–6%), and 
placebo–DMARD combination groups (2%–7%). Withdrawal 
due to lack of efficacy may be higher for tofacitinib 1–3 mg 
bid monotherapy groups (6%) compared with tofacitinib at 
higher doses (0%–2%) in one study,28 but not in the combina-
tion therapy studies.
In long-term extension studies, the rate of withdrawal 
secondary to all causes was reported to be 21% for tofacitinib 
5 mg bid or tofacitinib 10 mg bid, with or without background 
DMARD therapy.36 Although those receiving efficacy is 
achieved and sustained over 48 months, the efficacy over 
time was likely influenced by the decreased persistence on 
tofacitinib therapy over time.
In summary, total withdrawals and withdrawals due to 
lack of efficacy for tofacitinib appear to be similar or fewer 
than withdrawals from placebo or other comparators.
withdrawal for adverse drug reactions
During tofacitinib DMARD monotherapy studies, the per-
centage of withdrawals from tofacitinib secondary to adverse 
drug reactions ranged from 1% to 7% in studies lasting 
6 weeks to 6 months and increased to a range of 10%–13% in 
a 24-month study (Table 5).35 Additionally, these percentages 
remained comparable between the 5 and the 10 mg bid or 
20 mg od dose arms across the monotherapy studies. Studies 
of tofacitinib–DMARD combination from 12 weeks to 1 year 
demonstrated similar percent of withdrawal rates secondary 
to adverse events in the 5 and the 10 mg bid or 20 mg od 
dose arms, ranging from 1% to 14% (Table 5). There were 
no apparent consistent trends for withdrawal due to adverse 
effects when comparing tofacitinib with comparators or 
placebo (Table 5). Furthermore, discontinuations secondary 
to adverse effects in long-term extension studies occurred in 
11% of patients and had an incidence rate of 7.3 events per 
100 patient-years, with the most frequent types of adverse 
effects resulting in withdrawal due to laboratory study 
abnormalities, infestations and infections, and neoplasias.36 
Additional reported adverse drug reactions leading to trial 
withdrawal consisted of neutropenia, leukopenia, myocar-
dial ischemia, moderate bronchitis, lymphadenopathy, and 
pyelonephritis among others.25 In summary, withdrawals due 
to adverse effects increase with increased duration but are 
generally comparable across the different doses of tofacitinib 
and with placebo and other comparator DMARDs.
Serious adverse drug reactions
The percent of serious adverse events during tofacitinib 
DMARD monotherapy studies in the 5 and 10 mg bid arms 
appeared to increase with study duration from 0% to 7% in 
6-week to 6-month studies compared with 11% in a 24-month 
study (Table 5). Tofacitinib DMARD monotherapy studies 
with durations of 6 and 24 weeks reported no cases of serious 
adverse drug reactions in the 5 mg bid group, 2% occurrence 
in a 6-month study, and 11% occurrence in 24-month study. 
There was no apparent consistent pattern of increases in seri-
ous adverse drug reactions seen with higher doses compared 
with lower doses. In combination DMARD studies, tofacitinib 
was associated with similar occurrence of serious adverse drug 
events across all dosages of tofacitinib. In addition, long-term 
extension studies reported an incidence rate of 11.1 serious 
adverse events per 100 patient-years with 15% of patients 
experiencing serious adverse events.36 Similar to withdraw-
als due to adverse effects, the rates of serious adverse effects 
increased as study duration increased, but were generally 
comparable across the different doses of tofacitinib and with 
placebo and other comparator DMARDs.
Serious infections
The occurrence of serious infections in various studies ranged 
from 1% to 3% and was similar with respect to duration of 
therapy or intervention in both monotherapy and combination 
studies (Table 5). Incidence rates of 4.17 serious infections 
per 100 patient-years with tofacitinib 5 mg bid, 2.32 per 
100 patient-years with tofacitinib 10 mg bid, and 3.68 per 100 
patient-years with placebo were reported in a 1-year study.34 
Comparatively, serious infections occurred in 184 patients 
(4%) with an incidence rate of 3.1 events per 100 patient-
years during long-term extension studies.36
An analysis of infections in all prior Phase II, Phase III, 
and long-term extension studies was not used in the 
initial data, but provides data on predictors of serious 
infections.40 The independent predictors associated with 
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Table 5 Major safety events: serious adverse drug reactions, serious infections, cancers, deaths, and withdrawal due to lack of efficacy 
in tofacitinib studies
Event Number of events (% of group) Duration and 
referenceTofacitinib Placebo Comparator 
DMARD1–3 mg bid 5 mg bid 10 mg bid  
or 20 mg od
15–30 mg bid
Tofacitinib DMARD monotherapy studies
wd ADR 1 (2%) 9 (7%) 1 (2%) 6 weeks25
wd ADR 2 (2%) 1 (2%) 1 (2%) 2 (4%) 0 Adalimumab 
3 (6%)
24 weeks28
wd ADRs 3 (1%) 11 (4%) 5 (4%) 6 months30
wd ADRs 40 (11%) 41 (10%) Methotrexate 
25 (13%)
24 months35
wd ADRs 1 (1%) 2 (4%) 3 (6%) 0 2 (4%) 12 weeks38
Serious ADRs 0 2 (1%) 1 (2%) 6 weeks25
Serious ADRs 3 (3%) 0 1 (2%) 4 (7%) 2 (3%) Adalimumab 
1 (2%)
24 weeks28
Serious ADRs 6 (2%) 11 (4%) 0 6 months30
Serious ADRs 40 (11%) 43 (11%) Methotrexate 
22 (12%)
24 months35
Serious ADRs 3 (3%) 1 (2%) 1 (2%) 1 (2%) 0 12 weeks38
Serious infections 1 (,1%) 4 (1%) 2 (1%) 6 months30
Serious infections 11 (3%) 8 (2%) Methotrexate 
5 (3%)
24 months35
Serious infections 0 0 0 0 0 12 weeks38
Cancers 2 (1%) 3 (1%) Methotrexate 
1 (1%)
24 months35
Deaths 0 0 0 6 weeks25
Deaths 0 0 0 1 (2%) 0 Adalimumab 
0
24 weeks28
Deaths 0 1 (,1%) 0 6 months30
Deaths 3 (1%) 1 (,1%) Methotrexate 
0
24 months35
Tofacitinib combination DMARD studies
wd ADRs 2 (4%) 4 (14%) 4 (14%) 2 (7%) 12 weeks27
wd ADRs 3 (4%) 5 (4%) 1 (1%) 11 (7%) 7 (9%) 24 weeks29
wd ADRs 15 (8%) 15 (8%) 2 (2%) 6 months33
wd ADRs 14 (7%) 10 (5%) 3 (3%) Adalimumab 
19 (5%)
12 months31
wd ADRs 36 (11%) 26 (8%) 12 months32
wd ADRs 14 (4%) 20 (6%) 12 months34
Serious ADRs 2 (4%) 1 (4%) 2 (8%) 0 12 weeks27
Serious ADRs 10 (5%) 10 (5%) 6 (5%) 6 months33
Serious ADRs 12 (6%) 10 (5%) 2 (2%) Adalimumab 
2 (3%)
12 months31
Serious infections 1 (1%) 1 (1%) 2 (3%) 1 (1%) 0 24 weeks29
Serious infections 3 (2%) 2 (1%) 0 6 months33
Serious infections 3 (1%) 4 (2%) 1 (1%) Adalimumab 
0
12 months31
Deaths 0 0 0 0 12 weeks27
Deaths 1 (1%) 0 0 0 0 24 weeks27
Deaths 0 1 (1%) 0 6 months33
Deaths 1 (,1%) 0 0 Adalimumab 
1 (,1%)
12 months31
Deaths 1 (,1%) 1 (,1%) 0 12 months32
Deaths 4 (1%) 1 (,1%) 1 (1%) 12 months34
Tofacitinib monotherapy and combination DMARD study
wd ADRs 437 (11%) 60 months36
Serious ADRs 630 (15%) 60 months36
Serious infections 184 (4%) 60 months36
Cancers 107 (2%) .42 months40
Cancers 60 (1%) 60 months36
Deaths 31 (1%) 60 months36
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Tofacitinib and patient outcomes in rheumatoid arthritis
(hazard ratio [HR]: 2.17; [95% confidence interval (CI): 
1.76–2.88]),  diabetes (1.99 [1.39–2.85]), corticosteroid use 
of $7.5 mg (1.4 [1.05–1.88]), and tofacitinib 10 mg bid dose 
(1.4 [1.13–1.83]).40 In summary, the risk for serious infections 
is relatively low, is not associated with length of study or dose, 
and is similar to placebo and other comparators.
Cancers
The reported number of cases of cancer appeared to be low 
in these studies, ranging from 0% to 2%, and did not appear 
to be related to the dose or duration of treatment (Table 5). 
A Phase III 24-month study reported six cases of confirmed 
cancer, five of which occurred in those on tofacitinib 5 and 
10 mg bid therapy, and one in a patient in the methotrexate 
group.35 The types of cancer reported included Burkitt’s 
B-cell lymphoma, non-Hodgkin’s lymphoma, colon cancer, 
chronic lymphocytic leukemia, prostate cancer, and gastric 
cancer. These cases represented 1% of participants from each 
group, which is comparable to the 1% of total participants 
with malignancies with an incidence rate of 1.0 events per 
100 patient-years reported in the long-term extension stud-
ies.36 The number of cancers reported was small, so it is dif-
ficult to make conclusions other than to report the occurrence. 
A recent report that pooled data from prior studies, revealed 
107 cancers in 5,671 patients (1.9%) (Table 5).41 The develop-
ment of cancers was similar to the expected rate in patients 
with moderate-to-severe rheumatoid arthritis and did not 
appear to increase as the duration of therapy increased.41
Deaths
The occurrence of death reported in tofacitinib studies 
appeared to be low and did not appear to be related to dose 
or study duration. The death rate ranged from 0% to 1% 
in monotherapy and combination studies of 6 weeks to 
24 months duration (Table 5). A death rate of less than 1% 
was reported during the long-term extension studies, with 
an incidence rate of 0.5 events per 100 patient-years.36 The 
number of deaths reported in these studies was also small, 
making it difficult to make conclusions.
Discussion
In addition to clinical and laboratory measures of disease 
activity, patient-reported and other patient-specific outcomes 
are also essential measures of effectiveness and safety in eval-
uating therapy in patients with rheumatoid arthritis. Patients’ 
perception of pain and ability to perform daily activities are 
important measures of their satisfaction with the treatment of 
their disease, particularly in a chronic inflammatory disease 
such as rheumatoid arthritis. Adverse consequences from 
chronic therapies may lead to discontinuation of therapy 
or development of additional disease burden or death. This 
focused review of the impact of tofacitinib on these patient 
outcomes is needed to further understand and determine the 
appropriate use of tofacitinib in rheumatoid arthritis. This 
review also extends the number of studies covered in prior 
reviews and meta-analyses.
The major results of this review are that tofacitinib 
5 mg bid (the approved dosage in the USA) and other doses 
are associated with clinically and statistically significant 
improvements in the HAQ-DI and other patient-reported 
composite outcomes measures. These findings are similar 
to findings reported in prior meta-analyses, but this review 
includes all patient-centered outcomes mentioned in the 
studies reviewed and also includes data from more recent 
studies.14,16 Measurements of patient’s pain and global 
assessment of disease demonstrated that tofacitinib 5 mg 
bid was more effective than both placebo and tofacitinib 
1–3 mg bid in both monotherapy and combination therapy 
studies.
Total withdrawals and withdrawals due to lack of efficacy 
appear to be fewer from the tofacitinib groups than those from 
placebo and comparator groups. These observations appear 
to be consistent with results from a meta-analysis, which 
reported that fewer subjects withdrew from the tofacitinib 
group than from the placebo group overall and due to lack 
of efficacy.17
Withdrawal rates due to adverse effects or lack of effi-
cacy showed no apparent consistent pattern between dosage 
ranges, placebo, or comparator drug categories. The only 
noticeable trend was an increase in total withdrawal rates 
as the length of the study increased. This increase was also 
observed in placebo and comparator drug groups, but was not 
associated with tofacitinib dosage group. One monotherapy 
study reported a higher withdrawal rate due to lack of efficacy 
in the tofacitinib 1–3 mg bid group compared with tofacitinib 
5 mg bid and higher doses, but combination studies did not 
show this effect.
Our review indicates that withdrawals due to adverse 
effects are generally comparable across the tofacitinib 
dosage groups, placebo, and other comparator DMARD 
groups. This was reported in an earlier meta-analysis of 
tofacitinib, which found that although the rate of withdrawal 
due to adverse effects was higher in the tofacitinib group 
than the placebo group, the difference was not statisti-
cally significant.17 Therefore, more recent studies have not 
altered these overall findings regarding withdrawal due to 
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Incidences of serious adverse reactions were similar 
in all dosage groups, placebo, and comparator studies. 
Infection was a common adverse event leading to tofacitinib 
withdrawal. However, the risk of serious infections seems 
to be similar to placebo and other comparators and was not 
associated with study duration. Our observation includes 
more recent studies but is similar to that of a meta-analysis, 
which reported nonstatistical difference in incidences of 
infections between tofacitinib and placebo.12,14,16,17 The 
long-term extension study reported independent predictors 
associated with increased risk of serious infections, which 
included age $65 years, presence of diabetes, corticoster-
oid use of $7.5 mg od of prednisone (or equivalent), and 
tofacitinib 10 mg bid.36 These predictors may help clini-
cians to determine which patients on tofacitinib to closely 
monitor for serious infections. Tofacitinib may decrease 
the response to some vaccines and therefore clinicians may 
consider administering vaccines prior to initiation of therapy 
with tofacitinib when possible to prevent the development 
of serious infections.42
The occurrence of cancer and death were low in this 
review and did not appear to be associated with study duration 
or study group (tofacitinib, placebo, or comparator DMARD). 
Cardiovascular disease is a major cause of death in patients 
with rheumatoid arthritis and that risk may be decreased 
or increased with DMARDs.43,44 However, further study is 
needed to determine the impact of tofacitinib on overall death 
rates and cardiovascular disease-associated deaths.
The limitations of this review are based on two major 
factors: the limitations of the duration and data provided in 
the available studies and the nature of the review. The data 
collected for this review were primarily from controlled 
clinical studies of 1 year or less in duration. Those data may 
or may not reflect the impact on patient outcomes during 
routine, long-term use of tofacitinib in rheumatoid arthritis. 
However, this is expected given the relatively short time 
since tofacitinib was approved. As more postmarketing 
data are collected, pharmacovigilance studies are needed 
to monitor the long-term safety and efficacy of this agent. 
The number of patient-reported composite measures was 
mostly limited to the HAQ-DI. This is a valid, reliable, and 
useful measure, but has its limitations in what is measured. 
Additional data on the impact of tofacitinib on the ability 
of patients to be productive in their personal and work life 
would be valuable additions. Many other patient outcome 
measures are available for use in future studies.
As noted above, the submissions for approval of 
tofacitinib were approved in the USA and numerous other 
countries, but not by the EMA following their initial and 
subsequent examinations in 2013.7 Specifically,
The CHMP [Committee for Medicinal Products for Human 
Use] had major concerns about the overall safety profile of 
Xeljanz. There were significant and unresolved concerns 
about the risk and type of serious infections seen with 
tofacitinib, which are related to the immunosuppressant 
action of the medicine. These safety concerns also included 
a risk of other severe side effects including certain cancers, 
gastro-intestinal perforations, (holes in the wall of the 
gut), liver damage and problems with increased lipid (fat) 
levels in the blood. It was not clear that these risks could 
be managed successfully in medical practice. … However, 
the lack of robust evidence on prevention of structural 
damage with Xeljanz in the proposed dose and population 
still contributed to the Committee’s view that the benefits 
of treatment did not outweigh significant and unresolved 
concerns about safety.7
The FDA approved tofacitinib, indicating the following 
on efficacy and concerns related to adverse effects:
In all of the trials, patients treated with Xeljanz experienced 
improvement in clinical response and physical functioning 
compared to patients treated with placebo. The use of Xeljanz 
was associated with an increased risk of serious infections, 
including opportunistic infections (infections that occur pri-
marily when the immune system is suppressed), tuberculosis, 
cancers and lymphoma. Xeljanz carries a Boxed Warning 
regarding these safety risks. Xeljanz treatment is also associ-
ated with increases in cholesterol and liver enzyme tests and 
decreases in blood counts. The FDA approved Xeljanz with 
a Risk Evaluation and Mitigation Strategy (REMS), which 
consists of a Medication Guide advising patients about impor-
tant safety information and a communication plan to inform 
health care providers about the serious risks associated with 
Xeljanz. To study the long-term effects of Xeljanz on heart 
disease, cancer, and serious infections, the FDA is requiring 
a postmarketing study that will evaluate two doses of Xeljanz 
and include a group of patients on another approved treatment 
to serve as a comparison.45
The effect of tofacitinib on cardiovascular events is 
complex. Cardiovascular events are increased in patients 
with rheumatoid arthritis, particularly in those with increased 
disease activity. A recent analysis has revealed that tumor 
necrosis factor inhibitors and methotrexate are associated 
with decreasing that risk.46 Both tofacitinib and tumor necro-
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Tofacitinib and patient outcomes in rheumatoid arthritis
rheumatoid arthritis. However, tofacitinib leads to an increase 
in total, low-density lipoprotein, and high-density lipopro-
tein cholesterol in patients, resulting in potential addition of 
lipid-lowering therapies. It is still too early to determine the 
effect of tofacitinib on the risk of cardiovascular events in 
patients with rheumatoid arthritis.
This review is limited by its nature as a review rather 
than being a prospective or retrospective study. It also lacks 
the statistical analyses associated with a meta-analysis. 
Additionally, this review included only published papers and 
may therefore be limited by publication bias of only those 
papers that have demonstrated a positive outcome. However, 
this review utilized strict criteria for study inclusion and data 
selection and provided data from all recent studies meeting 
those criteria.
Conclusion
Based on the evidence available and prior reviews and meta-
analyses,12–20 tofacitinib 5 mg bid appears to have a favorable 
impact on patient outcomes related to efficacy and safety, 
particularly when compared with placebo and comparator 
DMARDs. Increases in quality of life and functionality are 
significant and the overall discontinuation rate due to adverse 
effects and lack of efficacy are similar or better in some studies 
versus comparator DMARDs and placebo. Currently, tofaci-
tinib appears to have an important role in the treatment of 
rheumatoid arthritis through improvement in these patient 
outcomes and a safety profile that is similar to comparator 
drugs in the studies presented to date. However, the approval 
by some countries but not others plus the requirements for 
risk evaluation and mitigation strategies and for postmarket-
ing surveillance raise some concerns about the benefit-to-risk 
ratio of tofacitinib. Data from future clinical studies and post-
marketing surveillance will clarify the benefit-to-risk ratio of 
tofacitinib in the treatment of rheumatoid arthritis.
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